SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

ONB Number:	3235-0287
Estimated average burg	len
hours per response:	0.5

Section	this box if no lo n 16. Form 4 or	Form 5												r: erage burder	3235-0287 1		
	ions may contir tion 1(b).	iue. See		File		t to Section 16(a tion 30(h) of the					1934			hours	per res	ponse:	0.5
1. Name and Address of Reporting Person [*] <u>TRYNISKI MARK E</u>					2. Issuer Name and Ticker or Trading Symbol <u>CONMED CORP</u> [CNMD]								lationship o ck all applic Directo	able)	Reporting Person(s) to Issuer ble) 10% Owner		
(Last) 1964 PE	(Fi NFOLD WA	irst) \Y	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/01/2020								(give title		Other (s below)	pecify
(Street) BALDWINSVILLE NY 13027						endment, Date o	f Original	Filed	(Month/Day	/Year)		6. Ind Line) X	Form fi	ed by One ed by More	Repo	(Check App rting Persor One Repor	ı
(City)	(S	tate)	(Zip)									Person					
		Tá	ble I - Nor	n-Deriv	ative Se	ecurities Aco	quired,	Disp	posed of	, or Be	enef	icially	Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month/			action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	3. Transa Code (8)						5. Amoun Securities Beneficia Owned Fo Reported	s Ily ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) c (D)	^{or} I	Price	Transacti (Instr. 3 a	on(s)			(1130. 4)
Common Stock 06/01					L/2020		М		1,876	A		\$ <mark>0</mark>	42,	389		D	
						urities Acqu ls, warrants							Dwned				
1. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date. Transacti							5. Date Exercisable and 7. Title and Amount of					8. Price of 9. Numb			10. Ownership	11. Nature	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	n Date e (Month/Day/Year)	Date	Date	Date	Date	Date		Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nun Deriva Securi Acquir or Dis of (D) 3, 4 an	tive ties red (A) posed (Instr.	6. Date Exerci Expiration Dat (Month/Day/Ye	e	7. The and Amount of Securities Underlying Derivative (Instr. 3 ar	f 9 Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)																																																																		
Rsus (restricted Stock Units)	\$0	06/01/2020		М			1,876	06/01/2020 ⁽¹⁾	06/03/2029	Common Stock	1,876	\$0	0	D																																																																	
Rsus (restricted Stock Units)	\$0	06/01/2020		A		1,521		06/01/2021 ⁽²⁾	06/01/2030	Common Stock	1,521	\$0	1,521	D																																																																	
Options To Purchase Common Stock	\$73.94	06/01/2020		А		1,843		06/01/2021 ⁽³⁾	06/01/2030	Common Stock	1,843	\$0	1,843	D																																																																	

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period.

3. The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.

<u>Sarah M Oliker for Mark E.</u> <u>Tryniski by Power of Attorney</u>	<u>06/03/2020</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.